Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic polymorphism in drug oxidation.

W Kalow1

  • 1Department of Pharmacology, University of Toronto, Canada.

Psychopharmacology Series
|January 1, 1989
PubMed
Summary
This summary is machine-generated.

Drug oxidation polymorphisms, particularly debrisoquine polymorphism, significantly impact drug metabolism and patient outcomes. Understanding these genetic variations is crucial for effective pharmacotherapy and avoiding adverse drug reactions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pharmacogenetics and pharmacogenomics: origin, status, and the hope for personalized medicine.

The pharmacogenomics journal·2006
Same author

A simple test for acetylator phenotype using caffeine. 1984.

British journal of clinical pharmacology·2004
Same author

Both populations and individuals are evolutionary targets: pharmacogenomic and cultural indicators.

The pharmacogenomics journal·2002
Same author

Multigenic traits and risk assessment in pharmacology: a population approach.

The pharmacogenomics journal·2002
Same author

Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the C-->A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine.

Journal of clinical psychopharmacology·2002
Same author

Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine.

European journal of clinical pharmacology·2001
Same journal

Structure-function analysis of the three beta-adrenergic catecholamine receptors.

Psychopharmacology series·1993
Same journal

Molecular modeling of neurotransmitter receptors and ligands.

Psychopharmacology series·1993
Same journal

Brain serotonin subsystem complexity and receptor heterogeneity: therapeutic potential of selective serotonin agonists and antagonists.

Psychopharmacology series·1993
Same journal

Relevance of 5-HT autoreceptors for psychotropic drug action.

Psychopharmacology series·1993
Same journal

Developmental regulation of 5-HT2 and 5-HT1c receptor gene expression in rat brain.

Psychopharmacology series·1993
Same journal

Analysis of 935 haloperidol concentration measurements obtained during routine drug monitoring of 134 patients.

Psychopharmacology series·1993
See all related articles

Area of Science:

  • Pharmacogenetics
  • Drug Metabolism
  • Biochemistry

Background:

  • Two major drug oxidation polymorphisms exist: debrisoquine and mephenytoin hydroxylase.
  • Debrisoquine polymorphism affects a wider range of drugs compared to mephenytoin hydroxylase.
  • Recent studies have identified new substrates for debrisoquine hydroxylase, expanding its known impact.

Purpose of the Study:

  • To review the clinical significance of drug oxidation polymorphisms, focusing on debrisoquine hydroxylase.
  • To highlight the impact of genetic variations in drug metabolism on therapeutic outcomes.
  • To discuss factors influencing drug fate despite metabolic alterations.

Main Methods:

  • Literature review of established drug oxidation polymorphisms.
  • Analysis of known polymorphic substrates for debrisoquine and mephenytoin hydroxylases.

Related Experiment Videos

  • Examination of clinical implications, including drug interactions and toxicity.

    • Main Results:

    • Debrisoquine hydroxylase polymorphism impacts 28 identified drug substrates.
    • Clinical outcomes are significantly affected in poor metabolizers for nearly half of these drugs.
    • Drug-drug interactions, such as inhibition by quinidine and neuroleptics, can cause serious toxicity.

    Conclusions:

    • Debrisoquine polymorphism has broad clinical implications for drug therapy.
    • Understanding metabolic variations is essential for personalized medicine.
    • Pharmacogenetic studies inform therapeutic strategies even in individuals without genetic defects.